Remimazolam besylate for the sedation of postoperative patients undergoing invasive mechanical ventilation in the ICU: a prospective dose-response study

被引:8
作者
Chen, Xiaoyan [1 ,2 ]
Zhang, Jiancheng [1 ,2 ]
Yuan, Shiying [1 ,2 ]
Huang, Haiyan [1 ,2 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Crit Care Med,Inst Anesthesia & Crit Care Me, 1277 Jiefang Ave, Wuhan 430022, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Inst Anesthesia & Crit Care Med, Wuhan 430022, Peoples R China
基金
中国国家自然科学基金;
关键词
CLINICAL-PRACTICE; BISPECTRAL INDEX; NARCOTREND; PROPOFOL; MIDAZOLAM; DEXMEDETOMIDINE; ANESTHESIA; SLEEP;
D O I
10.1038/s41598-022-20946-6
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
This single-center study aimed to determine the effective dose and safety of remimazolam besylate for the sedation of postoperative patients undergoing invasive mechanical ventilation in the intensive care unit (ICU). Mechanically ventilated patients admitted to the ICU after surgery were included. The Narcotrend index (NTI) was used to assess the depth of sedation, and the Richmond Agitation-Sedation Scale (RASS) score was also recorded. Remimazolam besylate was administered initially at a loading dose of 0.02 mg/kg, followed by a gradual increase of 0.005 mg/kg each time until the targeted depth of sedation was achieved (NTI 65-94). A maintenance dose of remimazolam besylate was administered starting at 0.2 mg/kg/h, followed by increments or subtractions of 0.05 mg/kg/h each time until a satisfactory depth of sedation was achieved and maintained for at least 30 min. The demographic data, anesthesia, surgery types, hemodynamics and respiratory parameters were recorded. Adverse events and adverse drug reactions were monitored for safety. Twenty-three patients were eventually included in this study covering a period of 1 year. A satisfactory depth of sedation was achieved by a single intravenous infusion of remimazolam besylate at a loading dose of 0.02-0.05 mg/kg followed by a maintenance dose of 0.20-0.35 mg/kg/h. There were no significant changes in hemodynamic and respiratory parameters within 10 min after the administration of remimazolam besylate. In addition, a significant correlation was observed between the NTI and the RASS score for assessing sedation (r = 0.721, P < 0.001). The NTI showed a predictive probability for a RASS score of 0.817. Remimazolam besylate was effective for mild/moderate sedation of invasively mechanically ventilated postoperative patients in the ICU while maintaining excellent respiratory and hemodynamic stability. The NTI can be used as a good tool for the objective evaluation of the depth of sedation and agitation.
引用
收藏
页数:9
相关论文
共 29 条
  • [1] Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit
    Barr, Juliana
    Fraser, Gilles L.
    Puntillo, Kathleen
    Ely, E. Wesley
    Gelinas, Celine
    Dasta, Joseph F.
    Davidson, Judy E.
    Devlin, John W.
    Kress, John P.
    Davidson, Judy E.
    Devlin, John W.
    Kress, John P.
    Joffe, Aaron M.
    Coursin, Douglas B.
    Herr, Daniel L.
    Tung, Avery
    Robinson, Bryce R. H.
    Fontaine, Dorrie K.
    Ramsay, Michael A.
    Riker, Richard R.
    Sessler, Curtis N.
    Pun, Brenda
    Skrobik, Yoanna
    Jaeschke, Roman
    [J]. CRITICAL CARE MEDICINE, 2013, 41 (01) : 263 - 306
  • [2] EFFECTS OF INTRAVENOUS DEXMEDETOMIDINE IN HUMANS .1. SEDATION, VENTILATION, AND METABOLIC-RATE
    BELLEVILLE, JP
    WARD, DS
    BLOOR, BC
    MAZE, M
    [J]. ANESTHESIOLOGY, 1992, 77 (06) : 1125 - 1133
  • [3] A Phase IIa, Randomized, Double-Blind Study of Remimazolam (CNS 7056) Versus Midazolam for Sedation in Upper Gastrointestinal Endoscopy
    Borkett, Keith M.
    Riff, Dennis S.
    Schwartz, Howard I.
    Winkle, Peter J.
    Pambianco, Daniel J.
    Lees, James P.
    Wilhelm-Ogunbiyi, Karin
    [J]. ANESTHESIA AND ANALGESIA, 2015, 120 (04) : 771 - 780
  • [4] Induction and maintenance of procedural sedation in adults: focus on remimazolam injection
    Chen, Weiyun
    Chen, Shaohui
    Huang, Yuguang
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (04) : 411 - 426
  • [5] Devlin JW, 2018, CRIT CARE MED, V46, P1532, DOI [10.1097/CCM.0000000000003259, 10.1097/CCM.0000000000003299]
  • [6] Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial
    Doi, Matsuyuki
    Morita, Kiyoshi
    Takeda, Junzo
    Sakamoto, Atsuhiro
    Yamakage, Michiaki
    Suzuki, Toshiyasu
    [J]. JOURNAL OF ANESTHESIA, 2020, 34 (04) : 543 - 553
  • [7] Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III): results of a multicenter, randomized, double-blind, parallel-group comparative trial
    Doi, Matsuyuki
    Hirata, Naoyuki
    Suzuki, Toshiyasu
    Morisaki, Hiroshi
    Morimatsu, Hiroshi
    Sakamoto, Atsuhiro
    [J]. JOURNAL OF ANESTHESIA, 2020, 34 (04) : 491 - 501
  • [8] Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volunteers Part II. Pharmacodynamics of Electroencephalogram Effects
    Eisenried, Andreas
    Schuettler, Juergen
    Lerch, Marco
    Ihmsen, Harald
    Jeleazcov, Christian
    [J]. ANESTHESIOLOGY, 2020, 132 (04) : 652 - 666
  • [9] Monitoring sedation status over time in ICU patients - Reliability and validity of the Richmond Agitation-Sedation Scale (RASS)
    Ely, EW
    Truman, B
    Shintani, A
    Thomason, JWW
    Wheeler, AP
    Gordon, S
    Francis, J
    Speroff, T
    Gautam, S
    Margolin, R
    Sessler, CN
    Dittus, RS
    Bernard, GR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (22): : 2983 - 2991
  • [10] Remimazolam reduces sepsis-associated acute liver injury by activation of peripheral benzodiazepine receptors and p38 inhibition of macrophages
    Fang, Haihong
    Zhang, Yidong
    Wang, Jiancheng
    Li, Lulan
    An, Sheng
    Huang, Qiaobing
    Chen, Zhongqing
    Yang, Hong
    Wu, Jie
    Zeng, Zhenhua
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 101